Health Canada has approved ruxolitinib (Jakavi®) for the control of hematocrit in adult patients with polycythemia vera (PV) who are resistant to or intolerant of a cytoreductive agent.
Stay up to date
We need your help
The Canadian MPN Group relies on donor contributions to keep our work going. Can you help?